Ocean Bio-Chem joins coronavirus rall

Ultra-thinly traded nano cap Ocean Bio-Chem (OBCI +35.8%) is the latest tiny medical company to ride the wave of coronavirus outbreak-related buying.

In this case, it announced that subsidiary Star Brite’s disinfectant Performacide is registered with the EPA as a viricide effective against coronavirus when used as directed in the home or workplace.

https://seekingalpha.com/news/3535155-ocean-bio-chem-joins-coronavirus-rally-shares-up-36

HCA Q4 beat buoys hospital chains

Hospital operators are in the green after HCA reported better-than-expected Q4 results.

Selected tickers: Universal Health Services (UHS +1.3%), Surgery Partners (SGRY +0.7%), Select Medical Holdings (SEM +2.8%), Tenet Healthcare (THC +4.8%), Community Health Systems (CYH +3.4%), Humana (HUM +2%)

https://seekingalpha.com/news/3535219-hca-q4-beat-buoys-hospital-chains

FDA OKs Teva autoinjector for Ajovy

The FDA has approved an autoinjector device for Teva Pharmaceutical Industries’ (NYSE:TEVA) migraine med Ajovy (fremanezumab-vfrm). Market launch will commence in the coming months.
https://seekingalpha.com/news/3535397-fda-oks-teva-autoinjector-for-ajovy

Akcea Therapeutics up 6% after hours on positive AKCEA-ANGPTL3-Lrx data

Akcea Therapeutics (NASDAQ:AKCA) and majority owner Ionis Pharmaceuticals (NASDAQ:IONS) announce positive results from a Phase 2 clinical trial evaluating antisense oligonucleotide AKCEA-ANGPTL3-L_Rx in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).

The study met the primary endpoint of significant triglyceride lowering and multiple secondary endpoints with a favorable safety and tolerability profile.

There were statistically significant dose-dependent reductions in fasting triglycerides at all dose levels compared to placebo.

There were dose-dependent reductions in ANGPTL3, apoC-III, very low-density lipoprotein (VLDL-C), non-HDL cholesterol and total cholesterol compared to placebo.

No reductions were observed in liver fat or HbA1C levels versus placebo.

Detailed results will be submitted for presentation at a future medical conference.

https://seekingalpha.com/news/3535413-akcea-therapeutics-up-6-after-hours-on-positive-akcea-angptl3-lrx-data

Stryker Q4 non-GAAP earnings up 15%

Stryker (NYSE:SYK) Q4 results:

Sales: $4,131M (+8.8%); Orthopedics: $1,467M (+6.7%); MedSurg: $1,837M (+6.8%); Neurotech and Spine: $827M (+18.0%).

Net income: $725M (-64.9%); non-GAAP net income: $948M(+14.5%); EPS: $1.90 (-65.1%); non-GAAP EPS: $2.49 (+14.2%).

Cash flow ops (full year): $2,191M (-16.1%).

Q1 guidance: Non-GAAP EPS: $2.05 – 2.10.

2020 guidance: Sales growth: 6.5 – 7.5%; non-GAAP EPS: $9.00 – 9.20.

Stryker EPS beats by $0.03, beats on revenue

https://seekingalpha.com/news/3535431-stryker-q4-non-gaap-earnings-up-15

Accuray up 15% after hours on FQ2 beat

Accuray (NASDAQ:ARAY) fiscal Q2 results:

Revenue: $98.8M (-3.4%); net orders: $89.9M (+29.9%).

Backlog up 12% to $539.4M.

Net income: $10.7M (+332.6%); EPS: $0.12 (+340.0%).

Non-GAAP EBITDA: $7.1M (+73.2%).

Fiscal 2020 guidance: Revenue: $410M – 420M (unch); non-GAAP EBITDA: $21M – 26M from $19M – 24M (includes ~$1M expected loss from its JV in China).

Management does not believe that the coronavirus outbreak in China will affect the long-term demand for radiotherapy equipment there.

Shares up 15% after hours.

Accuray EPS beats by $0.19, beats on revenue

https://seekingalpha.com/news/3535449-accuray-up-15-after-hours-on-fq2-beat

Amphastar down 3% after hours on FDA rejection of epinephrine application

Amphastar Pharmaceuticals (NASDAQ:AMPH) slips 3% after hours in reaction to its announcement that it received a “Minor” Complete Response Letter (CRL) from the FDA regarding its marketing application for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose.

It submitted its response yesterday and expects a decision from the agency within three months.

https://seekingalpha.com/news/3535456-amphastar-down-3-after-hours-on-fda-rejection-of-epinephrine-application